Mitochondrial Oxidative Stress and Vascular Health in Chronic Kidney Disease



Status:Recruiting
Conditions:Renal Impairment / Chronic Kidney Disease
Therapuetic Areas:Nephrology / Urology
Healthy:No
Age Range:18 - Any
Updated:9/1/2017
Start Date:July 1, 2017
End Date:February 28, 2019
Contact:Danielle L Kirkman, PhD
Email:dkirkman@udel.edu
Phone:302 831 4659

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria
The purpose of this study is to examine the effect of mitochondria derived oxidative stress
on vascular function in patients with moderate to severe Chronic Kidney Disease.

Chronic Kidney Disease (CKD) patients are at increased risk of cardiovascular disease.
Endothelial dysfunction, characterized by a reduced bioavailability in nitric oxide, is an
independent predictor of cardiovascular disease in CKD. Increased oxidative stress is a
potential cause of endothelial dysfunction in this patient cohort. This study investigates
the role that mitochondrial derived oxidative stress plays in CKD related vascular
dysfunction. In a controlled, double blinded trial, Stage 3-5 CKD patients will be randomly
assigned to receive a 4 week daily dose of a mitochondria targeted antioxidant (MitoQ) or a
placebo.

Inclusion Criteria:

- Stage 3 - 5 Chronic Kidney Disease

Exclusion Criteria:

- History of cardiovascular disease;

- Current pregnancy;

- Uncontrolled hypertension;

- Uncontrolled hyperlipidemia;

- Current hormone replacement therapy;

- Current use of tobacco products;

- Elevated liver enzymes;

- Current autoimmune disease;

- Daily use of of antioxidants >300mg
We found this trial at
1
site
Department of Kinesiology and Applied Physiology, University of Delaware
Newark, Delaware 19713
Principal Investigator: Danielle Kirkman, PhD
?
mi
from
Newark, DE
Click here to add this to my saved trials